Wendell Glover, MD
Geriatric Medicine · Ridgeland, MSNPI 1336535053
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,381, more than ten times the $18 reported in 2021.
Across 143 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$373
- AstraZeneca$290
- Novo Nordisk$272
- Radius Health, Inc.$199
- Lilly USA, LLC$197
- Otsuka America Pharmaceutical, Inc.$177
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,175100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 13 | $373 |
| AstraZeneca | 18 | $290 |
| Novo Nordisk | 18 | $272 |
| Radius Health, Inc. | 8 | $199 |
| Lilly USA, LLC | 12 | $197 |
| Otsuka America Pharmaceutical, Inc. | 3 | $177 |
| Ironwood Pharmaceuticals, Inc | 7 | $166 |
| Phathom Pharmaceuticals, Inc. | 4 | $158 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $146 |
| Amgen | 8 | $130 |
| Inspire Medical Systems, Inc. | 1 | $122 |
| Abbott | 1 | $114 |
| Xeris Pharmaceuticals, Inc. | 1 | $97 |
| Bayer | 5 | $92 |
| Lundbeck LLC | 4 | $85 |
| Pfizer | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Harmony Biosciences LLC | 2 | $53 |
| Shield Therapeutics Inc | 3 | $50 |
| Ardelyx, Inc. | 2 | $50 |
| Novartis | 2 | $35 |
| Astellas Pharma US Inc | 2 | $33 |
| Exact Sciences | 2 | $29 |
| Boehringer Ingelheim | 2 | $28 |
| Corcept Therapeutics | 1 | $27 |
| GSK | 2 | $26 |
| AbbVie | 1 | $19 |
| Verona Pharma, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Averitas Pharma Inc. | 1 | $16 |
| NS Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$129
- REXULTI$125
- Auvelity$124
- Inspire$122
- FREESTYLE LIBRE 3$114
How this compares
Too few geriatric medicine providers in Mississippito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $64,895 |
| FarxigaDapagliflozin Propanediol | 31 | $41,520 |
| JardianceEmpagliflozin | 30 | $31,712 |
| EliquisApixaban | 30 | $28,903 |
| MounjaroTirzepatide | 15 | $20,017 |
| TrulicityDulaglutide | 14 | $19,707 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $15,662 |
| MyrbetriqMirabegron | 16 | $8,061 |
| Estradiol | 22 | $1,643 |
| Duloxetine Hcl | 66 | $1,568 |
| Rosuvastatin Calcium | 105 | $1,401 |
| Mometasone Furoate | 12 | $1,154 |
| Atorvastatin Calcium | 152 | $984 |
| Levothyroxine Sodium | 90 | $855 |
| Losartan Potassium | 69 | $673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $272 | $64,89562 claims |
| AstraZenecaFarxiga | $290 | $41,52031 claims |
| Lilly USA, LLCMounjaro, Trulicity | $197 | $39,72329 claims |
| Boehringer IngelheimJardiance | $28 | $31,71230 claims |
| PfizerEliquis | $69 | $28,90330 claims |
| GSKTrelegy Ellipta | $26 | $15,66217 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $8,06116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in Mississippion file to place this against a meaningful peer group, so we don't.
Other geriatric medicine in Ridgeland
- Rebecca HollingsworthHattiesburg$2K
- Russell BelenchiaUnion$712
- Amanda CooleyMagee$455
- Sara ParksJackson$451
- Kurt BruckmeierHattiesburg$445
- Holland AddisonJackson$387
- Vicky McLeanJackson$386
- Sara SandersJackson$310
- Kimberly Covington TarverJackson$208
- John HeyGreenwood$186
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.